Navigation Links
GSK and XenoPort Resubmit New Drug Application for Solzira(TM) in Restless Legs Syndrome
Date:1/9/2009

LONDON, RESEARCH TRIANGLE PARK, N.C. and SANTA CLARA, Calif., Jan. 9 /PRNewswire-FirstCall/ -- GlaxoSmithKline and XenoPort, Inc. announced today that GSK has resubmitted the New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) requesting approval of Solzira(TM) (gabapentin enacarbil) Extended Release Tablets for the treatment of moderate-to-severe primary Restless Legs Syndrome (RLS).

The FDA had requested that the data in a single study be reformatted. In addition, GSK conducted a review of other clinical studies taking this input into account. The withdrawal was not related to the content of the filing.

GlaxoSmithKline - one of the world's leading research-based pharmaceutical and healthcare companies - is committed to improving the quality of human life by enabling people to do more, feel better and live longer. For further information please visit www.gsk.com.

Solzira - is a new chemical entity that is designed to improve upon the pharmacokinetics of gabapentin by taking advantage of high-capacity transport mechanisms in the gastrointestinal tract to improve absorption.

XenoPort - is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilise the body's natural nutrient transport mechanisms to improve the therapeutic benefits of existing drugs. XenoPort is developing its lead product candidate in partnership with Astellas Pharma Inc. and GSK. As announced today, GSK has resubmitted to the FDA an NDA for Solzira for the treatment of moderate-to-severe primary RLS. XenoPort's product candidates are also being studied for the potential treatment of gastroesophageal reflux disease, migraine headaches, neuropathic pain, spasticity related to spinal cord injury, acute back spasms and Parkinson's disease. To learn more about XenoPort, please visit the Web site at www.XenoPort.com.

GlaxoSmithKline cautionary statement regarding forward-looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

XenoPort Forward-Looking Statement

This press release contains "forward-looking" statements, including, without limitation, all statements related to the therapeutic and commercial potential of XenoPort's product candidates. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon XenoPort's current expectations. Forward-looking statements involve risks and uncertainties. XenoPort' s actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the ability of the company to successfully conduct clinical trials of its product candidates, and the results thereof; the uncertainty of the FDA approval process and other regulatory requirements; XenoPort' s dependence on its current and additional collaborative partners; and the therapeutic and commercial value of the company' s compounds. These and other risk factors are discussed under the heading "Risk Factors " in XenoPort' s Quarterly Report on Form 10-Q for the quarter ended September 30, 2008, filed with the Securities and Exchange Commission on November 6, 2008. XenoPort expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the company's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.


'/>"/>
SOURCE GlaxoSmithKline; XenoPort, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
2. Transcept Pharmaceuticals Announces FDA Acceptance for Review of New Drug Application for Intermezzo(R)
3. OmegaGenesis Announces Angiogenesis Application Collaboration
4. t2cure Acquires Patent Family on In Vitro Potency Testing of Stem Cells for Cardiovascular Application
5. ISTA Pharmaceuticals Files New Drug Application with U.S. FDA for Bepreve(TM)
6. Call for Applications: The Amgen Award for Science Teaching Excellence
7. Savient Submits Biologics License Application (BLA) for pegloticase
8. GenOdyssee Receives Broad Product Applications Protection in EU for Founding Natural Evolution Technology
9. Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Submits New Drug Application to FDA for Carisbamate
10. Penn State gets $5M NSF grant for Nanotech Applications and Career Knowledge
11. FDA Continues Review of Takedas New Drug Application for Alogliptin (SYR-322), a DPP-4 Agent for Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/6/2016)... TORONTO , Dec. 6, 2016 /PRNewswire/ - SQI Diagnostics Inc. ("SQI" ... operational results for the fourth quarter and fiscal year ended September ... , , ... Toronto -based life sciences and diagnostics company that develops and ... Commercial Highlights Achieved revenues of $1.4 million ...
(Date:12/6/2016)... Fort Collins, Colorado (PRWEB) , ... December 06, ... ... developer of dynamic aqueous plasma technology platforms, announced today that the company has ... five-year Master Research and Development Agreement (MRDA) with the CSU Office of the ...
(Date:12/6/2016)... Dec. 6, 2016  SRI International has been ... from the National Institutes of Health,s National Institute ... of AIDS (NIAID-DAIDS) to support the manufacturing and ... (PreP) agents. Under the seven-year contract, SRI will ... services for candidate HIV-prevention products that emerge from ...
(Date:12/5/2016)... ... 2016 , ... This composition patent, U.S. Patent No. 9,499,637, ... composition claims are not limited to any particular process to make or use ... fibers, graphene, and other materials. A continuation application, U.S. Patent App. No. ...
Breaking Biology Technology:
(Date:12/6/2016)... , Dec. 6, 2016  Zimmer Biomet Holdings, Inc. ... has priced an offering of €500.0 million principal amount of ... principal amount of its 2.425% senior unsecured notes due 2026. ... to occur on December 13, 2016, subject to the satisfaction of ... annual basis. The Company intends ...
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/29/2016)... , Nov. 29, 2016 BioDirection, a privately ... products for the objective detection of concussion and other ... has successfully completed a meeting with the U.S. Food ... blood test Pre-Submission Package. During the meeting company representatives ... as a precursor to commencement of a planned pilot ...
Breaking Biology News(10 mins):